FogPharma is a United States based startup founded in 2015 and has garnered significant attention in the Biopharma, Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries. The company's slogan "Until everything is druggable" reflects its mission to revolutionize drug development. FogPharma is focused on developing a new class of drugs, HeliconTM peptides, which aim to overcome the limitations of current precision medicines and achieve universal druggability. By combining the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules, HeliconTM peptides hold the promise to effectively target almost all human disease drivers with unparalleled speed and scalability.
In the latest milestone, FogPharma raised a significant $145.00M Series E investment on 01 March 2024, with participation from notable investors including RA Capital Management, Marshall Wace, T. Rowe Price, 60 Degree Capital, Milky Way Ventures, Nextech Invest, Rock Springs Capital, Samsara BioCapital, VenBio Partners, and SymBiosis. This substantial investment demonstrates the confidence and support FogPharma has garnered within the investor community.
It's important to note that FogPharma is committed to maintaining the integrity of its recruitment process and warns prospective candidates about fraudulent activities. Authentic communication from FogPharma will be through the Greenhouse platform or email addresses ending in @fogpharma.com, and the company does not use LinkedIn messenger for job applicant communication. This cautionary notice reflects the company's dedication to maintaining transparency and protecting individuals from potential fraudulent activities.
